The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Careful Management Improves Safety of Stem Cell Transplantation in Crohn’s

Careful Management Improves Safety of Stem Cell Transplantation in Crohn’s

December 13, 2015 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Careful use of antibiotics and corticosteroids can substantially improve the safety of autologous hematopoietic stem transplantation (HSCT) in patients with refractory Crohn’s disease (CD), researchers from Spain report.

You Might Also Like
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • Stem Cell Transplantation Benefits Patients with Scleroderma
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights

“Autologous HSCT is feasible but it is associated with severe adverse events and even mortality,” Dr. Elena Ricart from Hospital Clinic de Barcelona tells Reuters Health by email. “Therefore, it is very important to adequately select the patients and refer those patients to experienced centers.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Autologous HSCT has been used for the past 20 years to control refractory immune-mediated diseases, including Crohn’s disease, although, due to safety concerns it is considered a salvage therapy for very severe and refractory patients,” she explains.

Dr. Ricart’s team reports on the results of 26 Crohn’s disease patients who underwent autologous HSCT at their center and describe measures they have undertaken to make the procedure safer.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

After severe complications related to mobilization and transplantation at the beginning of their experience, they revised the procedure by conducting drainage of perianal disease beforehand, implementing strict hygienic contact measures, and developing adequate antibiotic prophylaxis schedules.

Moreover, to reduce the likelihood of reactions to rabbit antithymocyte globulin (rATG) (used for T-cell depletion), they administered high-doses (500 mg) of corticosteroids before each infusion.

Perhaps as a result of these measures, there were no further cases of bacteremia, septic shock, or multidrug-resistant bacterial infections after the first five patients. However, six patients (29%, including four pretreated with high-dose corticosteroids) developed rATG reactions.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

One patient died during the first year of follow-up, the researchers report in Gut, online Nov. 19.

“Autologous HSCT may be considered for CD in patients with active disease uncontrolled by medical therapies, including immunomodulators, anti-TNF and vedolizumab—recently approved for CD, with extensive disease in which surgical resection would expose the patient to the risk of short small bowel syndrome,” Dr. Ricart says. “Also in refractory colonic disease and perianal lesions where proctocolectomy with a definitive stoma is not accepted by the patient.”

“The number of centers worldwide is limited, and it is recommended that these patients be referred to centers with experience and appropriate interdisciplinary interaction between hematological and CD specialists to select and manage CD patients,” Dr. Ricart adds. “Such centers should have JACIE [Joint Accreditation Committee for ISCT and EBMT] accreditation or equivalent.”

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: antibiotics, Crohn's disease, Oral Corticosteroids, Stem Cells

You Might Also Like:
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • Stem Cell Transplantation Benefits Patients with Scleroderma
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • Mesenchymal Stem Cell Therapy May Help Slow, Repair Degenerative Signs of Osteoarthritis, Musculoskeletal Disease

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)